

# 10-year survival of a patient with metastatic prostate cancer: Case report and literature review

---

Krpina, Kristian; Markić, Dean; Rahelić, Dražen; Ahel, Juraj; Rubinić, Nino; Španjol, Josip

Source / Izvornik: **Archivio Italiano di Urologia e Andrologia, 2015, 87, 252 - 253**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.4081/aiua.2015.3.252>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:184:711169>

Rights / Prava: [Attribution-NonCommercial 4.0 International/Imenovanje-Nekomercijalno 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-12-23**



Repository / Repozitorij:

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)




## 10-year survival of a patient with metastatic prostate cancer: Case report and literature review

Kristian Krpina, Dean Markić, Dražen Rahelić, Juraj Ahel, Nino Rubinić, Josip Španjol

Department of Urology, Clinical Hospital Center Rijeka, Rijeka, Croatia.

**Figure 2.**

*CT of the pelvis showing enlarged lymph nodes with dislocation of the bladder to the right side.*




**Figure 3.**

*Cystography showing bladder dislocation to the projection of right iliac bone.*



**Figure 4.**

*CT of the abdomen with no signs of disseminated disease.*



**Figure 5.**

*CT of the pelvis with no signs of disseminated disease and orthotopic position of the bladder.*



No conflict of interest declared.

## REFERENCES

1. Jemal A, Siegel R, Xu J, Ward E. *Cancer statistics, 2010*. *CA Cancer J Clin.* 60:277-300.
2. Ferlay J, Shin HR, Bray F, et al. *GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10*. Lyon, France: International Agency for Research on Cancer; 2010, accessed on 12.12.2012. Available from: <http://globocan.iarc.fr>
3. Sylvester RJ, Denis L, de Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. *European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol.* 1998; 33:134-43.
4. Montgomery RB, Goldman B, Tangen CM, et al. Southwest Oncology Group. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. *J Urol.* 2007; 178:1946-51.
5. Tangen CM, Faulkner JR, Crawford ED, et al. Ten-year survival in patients with metastatic prostate cancer. *Clin Prostate Cancer.* 2003; 2:41-5.
6. Eisenberger MA, Crawford ED, Wolf M, et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). *The National Cancer Institute Intergroup Study #0036. Semin Oncol.* 1994; 21:613-9.
7. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. *J Clin Oncol.* 2002; 20:3972-82.
8. Galsky M, Kelly WK. Use of nomograms for predicting survival in patients with castrate prostate cancer. *Urology.* 2003; 62 Suppl 1:119-27.